Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels

Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels

US Patent 10287317 · Granted May 14, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Portable solar-powered devices2024
Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (P2024
Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (P2024
Phenylalanine small organic compounds to directly modulate PCSK9 protein activit2024
Phenylalanine small organic compounds to directly modulate PCSK9 protein activit2024
Phenylalanine small organic compounds to directly modulate PCSK9 protein activit2024
Phenylalanine small organic compounds to directly modulate PCSK9 protein activit2024
Composition and methods of use of tetrahydroisoquinoline small molecules to bind2024
Composition and methods of use of tetrahydroisoquinoline small molecules to bind2024
Composition and methods of use of tetrahydroisoquinoline small molecules to bind2024
Composition and methods of use of tetrahydroisoquinoline small molecules to bind2024
Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulator2024